ALLO on Nasdaq
Allogene Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Senti Biosciences Holdings, Inc., Opthea Ltd or Enzon Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue - related party | $0 | $22.0K |
| Research and development | $150.2M | $192.3M |
| General and administrative | $56.8M | $65.2M |
| Impairment of long-lived asset | $2.4M | $15.7M |
| Total operating expenses | $209.3M | $273.2M |
| Loss from operations | -$209.3M | -$273.2M |
| Interest and other income, net | $19.3M | $20.2M |
| Interest expense | -$1.1M | -$181.0K |
| Other income (expense), net | $215.0K | -$3.9M |
| Total other income (expense), net | $18.4M | $16.1M |
| Loss before income taxes | -$190.9M | -$257.1M |
| Income tax expense | $0 | -$443.0K |
| Net loss | -$190.9M | -$257.6M |
| Net unrealized gain on available-for-sale investments | $358.0K | $866.0K |
| Net comprehensive loss | -$190.5M | -$256.7M |
| Net loss per share, basic (in dollars per share) | -$0.87 | -$1.32 |
| Net loss per share, diluted (in dollars per share) | -$0.87 | -$1.32 |
| Weighted-average number of shares used in computing net loss per share, basic (in shares) | 220.6M shares | 194.8M shares |
| Weighted-average number of shares used in computing net loss per share, diluted (in shares) | 220.6M shares | 194.8M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $51.7M | $75.2M | |
| Short-term investments | $198.5M | $217.3M | |
| Prepaid expenses and other current assets | $7.5M | $10.9M | |
| Total current assets | $257.7M | $303.4M | |
| Long-term investments | $8.0M | $80.7M | |
| Operating lease right-of-use asset | $39.9M | $45.2M | |
| Property and equipment, net | $72.8M | $86.1M | |
| Deposit placed in escrow | $23.5M | $20.8M | |
| Restricted cash | $10.3M | $10.3M | |
| Other long-term assets | $3.6M | $2.3M | |
| Total assets | $415.9M | $548.7M | |
| Accounts payable | $4.3M | $5.4M | |
| Accrued and other current liabilities | $28.2M | $30.1M | |
| Total current liabilities | $32.5M | $35.5M | |
| Lease liability, noncurrent | $75.0M | $83.2M | |
| Other long-term liabilities | $15.8M | $7.8M | |
| Total liabilities | $123.4M | $126.5M | |
| Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2025 and December 31, 2024; no shares were issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 229,413,523 and 212,210,597 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $229.0K | $212.0K | |
| Additional paid-in capital | $2.3B | $2.2B | |
| Accumulated deficit | -$2.0B | -$1.8B | |
| Accumulated other comprehensive gain (loss) | $269.0K | -$89.0K | |
| Total stockholders equity | $292.5M | $422.2M | $512.2M |
| Total liabilities and stockholders equity | $415.9M | $548.7M | |
| Preferred stock, par or stated value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 229.4M shares | 212.2M shares | |
| Common stock, shares outstanding (in shares) | 229.4M shares | 212.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$190.9M | -$257.6M |
| Stock-based compensation | $37.6M | $51.7M |
| Depreciation and amortization | $12.4M | $13.6M |
| Net amortization/accretion on investment securities | -$4.2M | -$8.3M |
| Impairment of long-lived asset | $2.4M | $15.7M |
| Impairment of equity investment and equity method investment | $0 | $2.0M |
| Non-cash rent expense | $4.4M | $5.3M |
| Income tax expense | $0 | $443.0K |
| Non-cash collaboration revenue - related party | $0 | -$14.0K |
| Share of loss from equity method investments | $0 | $1.7M |
| Deposit placed in escrow | -$2.7M | -$20.8M |
| Prepaid expenses and other current assets | $3.2M | -$492.0K |
| Other long-term assets | -$1.3M | $4.3M |
| Accounts payable | -$1.2M | -$503.0K |
| Accrued and other current liabilities | -$2.5M | -$1.3M |
| Operating lease liabilities | -$7.5M | -$6.3M |
| Other long-term liabilities | $1.1M | $259.0K |
| Net cash used in operating activities | -$149.2M | -$200.3M |
| Purchases of property and equipment | -$386.0K | -$694.0K |
| Proceeds from sales of investments | $0 | $5.4M |
| Proceeds from maturities of investments | $234.2M | $432.5M |
| Purchase of investments | -$138.3M | -$361.5M |
| Net cash provided by investing activities | $95.6M | $75.7M |
| Proceeds from issuance of common stock upon exercise of stock options | $0 | $813.0K |
| Proceeds from issuance of common stock under the employee stock purchase plan | $895.0K | $1.5M |
| Proceeds from CIRM award | $6.9M | $2.3M |
| Net cash provided by financing activities | $30.2M | $116.7M |
| Net decrease in cash, cash equivalents and restricted cash | -$23.5M | -$7.9M |
| Right-of-use asset obtained in exchange for lease liability | $0 | $2.4M |
| Property and equipment purchases in accounts payable and accrued and other current liabilities | $107.0K | $64.0K |
| Cash paid for amounts included in the measurement of lease liabilities | -$12.9M | -$12.5M |
Recent filings
- Sep 30, 2026SCHEDULE 13D/A
- Sep 2, 20268-K
- Aug 25, 20264
- Aug 21, 2026144
- Aug 20, 2026EFFECT
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Aug 12, 2026S-3
- Aug 7, 2026SCHEDULE 13G
- Aug 7, 2026SCHEDULE 13G/A
- Jul 6, 20264
- Jun 23, 20264
- Jun 23, 20264
- Jun 23, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10